Pharmaceuticals

Innovent Provides Key Results Update of IBI305 (Biosimilar Product Candidate of Bevacizumab) Compared with Bevacizumab

SUZHOU, China, June 3, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the study results for efficacy and safety of IBI305 (biosimilar of bevacizumab) comp...

2019-06-03 08:00 3223

Sihuan Pharm Post-launching Large-scale Clinical Trials of Cinepazide Maleate Injection were Completed With Efficacy Verified

HONG KONG, June 1, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) the largest cardio-cerebral vascular ("CCV") drug manufacturer inChina's prescription drug market, announced that the Group has completed the post-launch clinical trials of "Cinepazide Maleate Inject...

2019-06-01 11:18 1892

Iovance Biotherapeutics Expands Partnership with WuXi Advanced Therapies Business

PHILADELPHIA, May 31, 2019 /PRNewswire/ -- Iovance Biotherapeutics, a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, has expanded its relationship with WuXi AppTec's Advanced Therapies Business Unit (WuXi ATU). Wu...

2019-05-31 20:00 2905

Innovent Provides Update on Phase Ib Study of Sintilimab in Combination with Chemotherapy for First-line Advanced or Metastatic Non-small Cell Lung Cancer

SUZHOU, China, May 31, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the preliminary results of sintilimab, the anti-PD-1 antibody that co-developed with...

2019-05-31 08:00 4187

Conagen announces formation of Scientific Advisory Board

Board includes five world-leading scientists in the fields of Synthetic Biology and Applied Molecular Biology  BEDFORD, Massachusetts, May 30, 2019 /PRNewswire/ -- Conagen Inc., a vertically integrated synthetic biology and fermentation company, announced today the formation of a new scientific ...

2019-05-30 20:00 2150

CartiHeal's Agili-C™ Implant Enhances In-vitro Osteogenic Differentiation of Human Bone Marrow-derived Mesenchymal Stem Cells

KFAR SABA, Israel, May 30, 2019 /PRNewswire/ -- CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of osteochondral and chondral defects, announced today the publication of anin-vitro study demonstrating that the Agili-C™ implant enhances osteogenic differentiation of human...

2019-05-30 20:00 1986

Luye Pharma's Rykindo® NDA Filing Accepted by the U.S. FDA

SHANGHAI, May 30, 2019 /PRNewswire/ -- Rykindo® (LY03004), Luye Pharma's innovative, independently developed Extended-Release Microspheres formulation for injection, is one step closer to going on the U.S. market. The US Food and Drug Administration (FDA) has completed the filing review and acce...

2019-05-30 13:09 2641

PHS Health Solutions Unveils Company Rebrand to Amplity Health

New Brand Identity Sets the Stage for a New Pure-play Commercialization Partner to the Pharmaceutical Industry YARDLEY, Pennsylvania, May 29, 2019 /PRNewswire/ -- PHS Health Solutions (PHS), a leading pharmaceutical contract commercial organization with an exemplary 35-year track record as ...

2019-05-29 22:00 1683

Sihuan Pharm Obtained Phase I to III Clinical Trial Approval for the Third Generation of EGFR Inhibitor XZP-5809

HONG KONG, May 29, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular ("CCV") drug manufacturer inChina's prescription drug market, announced the third generation of EGFR inhibitor XZP-5809, a Category 1 innovative drug developed by t...

2019-05-29 18:00 4929

IMI launches IMI Corporate Wellness amidst growing concerns for professionals' wellbeing.

HONG KONG, May 28, 2019 /PRNewswire/ -- Integrated Medicine Institute (IMI), Hong Kong's largest natural and integrated medicine clinic, today announced the official launch of its corporate wellness arm. Already at work in global organizations with a presence inHong Kong, IMI Corporate Wellness s...

2019-05-28 09:15 3483

After $7.1 Billion Sale Of Frutarom, Ori Yehudai To Join The Sade Group As Active Chairman and Investor

NESS ZIONA, Israel, May 27, 2019 /PRNewswire/ -- Ori Yehudai: "I took a company worth$3 million and sold it to IFF at $7.1 billion in 2018. In my opinion, the success of our cannabis company will be to build an industrial pharmaceutical company with the strictest standards, we had two such plants...

2019-05-27 20:05 2551

Sihuan Pharm Becomes the First Chinese Company that was Granted Approval for "Non-PVC Solid-Liquid Double Chamber Bag for Ceftazidime/Sodium Chloride Injection"

HONG KONG, May 27, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) ("Sihuan Pharmaceutical" or the "Group"), the largest cardio-cerebral vascular ("CCV") drug manufacturer in China's prescription drug market, announced the "non-PVC solid-liquid double chamber bag for ...

2019-05-27 17:08 5062

111 to Collaborate with MSH to Build Internet Pharmaceutical and Healthcare Service Closed-loop System

SHANGHAI, May 24, 2019 /PRNewswire/ -- Following 111, Inc.'s (NASDAQ: YI) ("111" or the "Company") strategic partnership with Manulife-Sinochem last year, the Company has reached another milestone. OnMay 24, 111 and MSH, a world leader in the design and management of international healthcare solu...

2019-05-24 22:45 8413

Elekta Unity MR-linac Receives Regulatory Approval From Japanese Ministry of Health, Labour and Welfare

With the potential to transform how clinicians treat cancer, Japan enters a new era of precision radiation medicine with magnetic resonance radiation therapy TOKYO, May 24, 2019 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that its Elekta Unity magnetic resonance radiation therapy system ha...

2019-05-24 07:05 7424

Cstone partner Agios Announces the Phase 3 ClarIDHy Trial of TIBSOVO (ivosidenib) Achieved its Primary Endpoint

SUZHOU, China, May 23, 2019 /PRNewswire/ -- The partner of CStone Pharmaceuticals ("Cstone"; HKEX:2616), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) ("Agios") announced that the global Phase 3 ClarIDHy trial of TIBSOVO (ivosidenib) in previously treated cholangiocarcinoma patients with an isocitr...

2019-05-23 18:36 3619

Phebra establishes new subsidiary in Canada and announces marketing approval for its IV Arsenic Trioxide Solution

SYDNEY, May 23, 2019 /PRNewswire/ -- Australian pharmaceutical firm Phebra (the 'Company') has continued its international business expansion with the opening of its subsidiary inMontreal, Canada. The new entity, Phebra Canada, will be headed byTony Romagnino, Vice President of Phebra's current N...

2019-05-23 17:00 1781

Bened Biomedical Co., Ltd.: Psychobiotic PS128(TM) found to be a potential solution for Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD)

TAIPEI, , May 23, 2019 /PRNewswire/ -- The possible correlation between autism spectrum disorder (ASD) and gut microbiota has long been explored. A recent study, published in《Nutrients》, shows that a specific probiotic supplementation composed ofLactobacillus plantarum PS128 (Psychobiotic PS128™,...

2019-05-23 11:45 2494

Menarini Ricerche at the ASCO Annual Meeting 2019 With Three Different Projects in Oncology

POMEZIA, Italy, May 23, 2019 /PRNewswire/ -- Menarini Ricerche will present three different projects related to the compounds in clinical development SEL24/MEN1703, MEN1611 and MEN1309/OBT076 at the ASCO Annual Meeting 2019 in Chicago. During the poster session "Breast Cancer – Metastatic" on Jun...

2019-05-23 08:00 2588

2019 Competitive Benchmarking of Leading Oncology Organizations: Commercialization Trends That are Shaping the U.S. Solid and Liquid Tumor Marketplaces

PharmaForce International's 2019 Oncology Studies benchmark key expenditures and organizational approaches of leading Oncology sales and marketing organizations around the globe.The United States is just one of five regions that PFI covers in the Oncology market. READING, Pennsylvania, May 23, 2...

2019-05-23 07:00 1555

China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province

TAIZHOU, China, May 22, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs"), announced today the laun...

2019-05-22 23:20 6982